SUMMARY In order to elucidate the mode of action of beta-adrenoreceptor antagonists in essential tremor, the efficacy of chronic oral administration of metoprolol, atenolol and sotalol was compared in a randomised, double-blind placebo controlled trial in twenty-four patients. Only sotalol proved superior to placebo on both subjective and "objective" assessments. Metoprolol and sotalol produced comparable degrees of beta-adrenoreceptor antagonism as judged by the blockade of standing tachycardia. Atenolol, in the dose used, produced a trend towards a greater cardiac chronotropic effect. These findings provide no support for the concept that central or peripheral beta,-adrenoreceptor mechanisms are important in essential tremor. The beneficial effect of beta-adrenoreceptor antagonists may be mediated predominantly through peripheral beta2-adrenoreceptor mechanisms.
Essential tremor is a common disorder which has been regarded as a form of exaggerated physiological tremor.' While physiological tremor, and the tremor of anxiety and thyrotoxicosis, appear to be mediated via peripheral beta2-adrenoreceptor mechanisms,2 the mode of action of betaadrenoreceptor antagonists in essential tremor remains contentious. Evidence from some clinical trials has supported the notion that the beneficial effects of such drugs are mediated mainly via peripheral beta2-adrenoreceptor mechanisms.34 However, studies utilising local intra-*arterial, or intravenous, injection of propranolol have implicated central mechanisms.5 In addition, recent reports have suggested that the cardio-selective beta-adrenoreceptor antagonist metroprolol may be effective in reducing the amplitude of essential tremor.6-9 Indeed, Ljung'°has proposed that central beta,-adrenoreceptor mechanisms may be important in this condition. Unfortunately, many of these studies were not adequately controlled. Some were single-blind or open studies, without placebo refer-ence, and often the dose of metoprolol may have been in excess of that preferentially acting on beta, adrenoreceptors. We have, therefore, carried out a double-blind placebo-controlled trial comparing metoprolol with atenolol and sotalol in patients with essential tremor. Atenolol, like metoprolol, is a relatively selective beta,-adrenoreceptor antagonist but, unlike metoprolol, it has difficulty entering the CNS." Sotalol, a non-selective antagonist acting mainly peripherally, '2 Patients with a history of diabetes mellitus, bronchial asthma or heart disease were excluded. All therapy was discontinued for two weeks prior to entry to the trial (the "run-in" period).
Protocol
The trial was double-blind and placebo controlled; it was conducted at three centres. Each patient was studied at least once, without any medication, during the two week "run-in" period, following which they were randomly allocated to treatment or placebo periods, each reduc6d by intravenous injection of propranolol.516
These observations led the authors to suggest that the effect of propranolol might be mediated by a central action, or possibly by way of a metabolite, since chronic oral administration appeared to be more effective than both intra-arterial and intravenous administration.5 Further doubt concerning the role of peripheral beta2-adrenoreceptor mechanisms in essential tremor arose from reports that metoprolol, a cardio-selective adrenoreceptor antagonist which enters the brain with relative ease, was beneficial.6-9 These observations led Ljung'°to suggest that central beta,-adrenoreceptor mechanisms might be important in essential tremor. In the present double-blind trial we compared metoprolol, atenolol and sotalol with placebo. We used a low dose of metoprolol (50 mg twice daily) in seventeen patients in order to avoid loss of cardioselectivity. A further seven patients received a higher dose of metoprolol (100 mg twice daily). Blockade of standing tachycardia and reduction in standing diastolic blood pressure were similar with all three drugs, although atenolol had a tendency to a greater effect upon standing tachycardia, and sotalol had a greater effect upon blood pressure than the other drugs. As it turns out, these comparative effects of the different beta-blockers on the rise in pulse rate on standing, and diastolic blood pressure on standing, add to the interpretation of their significance of their actions in essential tremor. Atenolol had more effect on pulse and blood pressure than sotalol, but had less effect on essential tremor. So beta2-antagonism appears to be important for tremor relief. For reasons already mentioned, the adrenoreceptors involved are likely to be peripheral, although with chronic treatment it is possible that even hydrophilic beta-adrenoreceptors such as atenolol and sotalol may enter the CNS in significant amounts. '7 However, despite its powerful beta,-antagonist actions and its central effects, metoprolol proved no better than placebo in doses of 50 mg or 100 mg twice daily, although it has been shown to have greater effects upon pulmonary beta2-adrenoreceptors (at a dose of 100 mg twice daily) than atenolol (100 mg daily).'8 This raises the possibility that atenolol exerts its beneficial effect at least partly via peripheral beta,-adrenoreceptor mechanisms.
Recent studies support our findings. Larsen and Teravainen'9 compared oral atenolol (100 mg daily), metoprolol (150 mg daily) and propranolol (240 mg daily) with placebo in a double-blind cross-over study in twenty-four patients with essential tremor. Propranolol was most, and metoprolol least effective in reducing the amount of tremor, although all drugs produced statistically significant decreases in the amount of tremor when compared with placebo. Calzetti et a120 have also compared metoprolol with propranolol. In an acute experiment, they gave single oral doses of metoprolol (150 mg), propranolol (120 mg) or placebo to essential tremor patients, and assessed the amount of tremor before and 1.5 hr after treatment. Both drugs produced an equivalent reduction in tremor, and both were superior to placebo. However, in a chronic cross-over study using two oral dosage regimes (150 mg and 300 mg daily for metoprolol and 120 mg and 240 mg daily for propranolol) only propranolol produced a statistically significant reduction in tremor when compared with placebo. In both acute and chronic experiments, the degree of blockade of standing tachycardia was the same for both beta- 
